Response to Swinnen et al.

Abstract

Diabetes Technology & TherapeuticsVol. 12, No. 6 Letter to the EditorOpen AccessResponse to Swinnen et al.Alan C. Moses and Christoph KoenenAlan C. MosesSearch for more papers by this author and Christoph KoenenSearch for more papers by this authorPublished Online:17 May 2010https://doi.org/10.1089/dia.2009.0186AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail Dear Editor:Interpretation of data from the comparison of two insulins in a clinical trial setting is challenging when the insulins are studied in different dosing regimens and their titration is performed using different algorithms. In a recent article, Swinnen et al.1 attempt to justify their design of L2T3, namely, the comparison of twice-daily detemir to once-daily glargine. However, differences in dosing regimens and the complexity of titration algorithms have the potential to impact all aspects of the results, including efficacy, safety, and patient-reported outcomes. Caution should be exercised when designing such a study, and even more caution should be exercised when interpreting the results.Swinnen et al. acknowledge that the benefits of insulin glargine and insulin detemir compared to those of neutral protamine Hagedorn (NPH) insulin had been established at the time the L2T3 study was designed.2–4 However, the authors questioned the efficacy of detemir in a once-daily regimen based on the results of one regulatory submission study5 and one other study, by Hermansen et al.,2 that evaluated detemir and NPH in twice-daily dosing regimens. While the regulatory submission study did demonstrate a greater decrease in hemoglobin A1c (HbA1c) with NPH and a similar decrease in fasting plasma glucose, less weight gain, and a lower risk of minor and nocturnal hypoglycemia with detemir, Hermansen et al.2 showed similar efficacy and confirmed less weight gain and a lower risk of overall and nocturnal hypoglycemia with detemir. It is important to consider several other published studies supporting the once-daily use of detemir, including pharmacokinetic/pharmacodynamic studies6,7 and randomized clinical trials in type 1 and type 2 diabetes.8–10 The labeling for detemir allowed for once- or twice-daily dosing at the time of the design of the study. It is regrettable that Swinnen et al. did not include a third arm in order to compare insulin glargine (once daily) to insulin detemir (once and twice daily).Swinnen et al. further reference a study of once-daily detemir versus once-daily NPH by Philis-Tsimikas et al.11 and, despite the similar efficacy observed in this study, raise doubts as to “whether such a strategy will help as many people achieve good control as NPH or glargine once daily.” They highlight final HbA1c values of 7.4% for both detemir and NPH as a concern. In fact, the overall changes in HbA1c from beginning to end of the study and the insulin doses used at the end of the study were similar to those observed in Riddle et al.,3 and Philis-Tsimikas et al.11 used a less aggressive insulin titration schedule. It is important to note that four separate studies with insulin glargine demonstrated comparable end points, with final HbA1c values above 7%.12–15Swinnen et al. also reference studies in which patients using detemir “required” a second daily injection16,17 but do not explain the study designs in these investigations. Rosenstock et al.16 required only patients using detemir—not those using glargine, because of labeling restrictions—to add a second daily dose if prespecified, pre-dinner titration targets were not achieved. In fact, a post hoc evaluation of this study indicated that a similar percentage of glargine patients would have required twice-daily dosing if the same titration schedule was applied to those patients using glargine.18 However, it cannot be known if patients injecting insulin glargine twice daily would have experienced the same effect on blood glucose as those patients injecting insulin detemir twice daily. A subanalysis of the 45% of patients who remained on once-daily insulin detemir in this study demonstrated equivalent efficacy, safety, and dosing between detemir and glargine and spurred the design of future trials that have studied detemir exclusively in a once-daily regimen in patients with type 2 diabetes taking oral antidiabetes drugs.11,19While Swinnen et al. attempt to justify the rationale behind the twice-daily dosing regimen for detemir in L2T3, a discussion of what has been learned since the design of the study was not provided. Specifically, the authors make no mention of the numerous studies supporting the once-daily use of detemir, including randomized controlled trials and large observational studies11,16,19–24 and clamp and continuous glucose monitoring studies demonstrating comparable time–action profiles between detemir and glargine.25,26 In fact, according to the 2009 American Association of Clinical Endocrinologists/American College of Endocrinology guidelines, “detemir can be used with 1 injection per day in patients with type 2 diabetes; excellent reproducibility of absorption profile within individuals; possibly less weight gain than with other insulins.”27 Current labeling for detemir in the countries participating in L2T3, including Europe, Canada, and Australia,28–30 recommends the use of detemir once daily in combination with oral antidiabetes drugs for the treatment of type 2 diabetes. While an exhaustive discussion of more recent data cannot be expected, some reference to current literature should have been provided, as it is important to acknowledge what has been learned since the design of L2T3 in order to place its design and anticipated results into perspective.Finally, although it has previously been demonstrated in patients with type 1 diabetes prior to the design of L2T3,31 Swinnen et al. also fail to acknowledge the now well-established concept that twice-daily dosing regimens of any basal insulin elevate the dose compared to once-daily regimens, with limited additional impact on glycemic control.16,32 The addition of a second basal dose also is likely to adversely impact hypoglycemia rates, weight gain, the prevalence of injection site reactions, and overall quality of life, including treatment satisfaction.31 This learning is important to share when discussing the design of L2T3 to ensure the results are discussed in proper perspective.In summary, only one study has evaluated insulin detemir and insulin glargine in a head-to-head comparison as an add-on to oral therapy in type 2 diabetes.16 The L2T3 study will contribute to the literature concerning the treatment of type 2 diabetes with basal insulin; however, any differences between insulin detemir and insulin glargine would have been more clearly identified had the analogs been studied in identical dosing regimens. It is reasonable to assume that any observed differences in outcomes between the two analogs in the L2T3 study may be a result of the different dosing regimens, especially with respect to dosage, hypoglycemia, and patient-reported outcomes, as well as the inherent differences between the analogs. The results from the L2T3 study, together with those from an ongoing study comparing insulin detemir and insulin glargine in identical, once-daily dosing regimens (the Effect of Insulin Determir and Insulin Glargine on Blood Glucose Control in Subjects with Type 2 Diabetes [EFFICACY™] trial [identified as NCT00909480 at http://www.clinicaltrials.gov]), will provide valuable information about the use of these analogs in the treatment of type 2 diabetes and will benefit the diabetes community.AcknowledgmentsThe authors wish to thank Rebecca Shaffer, Ph.D., of Novo Nordisk Inc. and Lisa Sullivan of Watermeadow Medical USA for editorial assistance in preparing this letter for publication. Funding for editorial assistance was provided by Novo Nordisk Inc.Author Disclosure StatementA.C.M. and C.K. are employees of and shareholders in Novo Nordisk.References1 Swinnen SGHASnoek FJDain M-PDeVries JHHoekstra JBLHolleman FRationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-to-Target (L2T3) study: a multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetesDiabetes Technol Ther200911739743.1. Swinnen SGHA, Snoek FJ, Dain M-P, DeVries JH, Hoekstra JBL, Holleman F: Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-to-Target (L2T3) study: a multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. Diabetes Technol Ther 2009;11:739–743. Link, Google Scholar2 Hermansen KDavies MDerezinski TMartinez Ravn GClauson PHome PA 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naïve people with type 2 diabetes. Diabetes Care 2006;29:1269–1274Erratum in: Diabetes Care2007301035.2. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naïve people with type 2 diabetes. Diabetes Care 2006;29:1269–1274. Erratum in: Diabetes Care 2007;30:1035. Crossref, Google Scholar3 Riddle MCRosenstock JGerich JInsulin Glargine 4002 Study InvestigatorsThe treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patientsDiabetes Care20032630803086.3. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080–3086. Crossref, Medline, Google Scholar4 Horvath KJeitler KBerghold AEbrahim SHGratzer TWPlank JKaiser TPieber TRSiebenhofer ALong-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitusCochrane Database Syst Rev20072CD005613.4. Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A: Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(2):CD005613. Medline, Google Scholar5 European Medicine Agency: Levemir European Public Assessment ReportRevision 1022July2008http://www.emea.europa.eu/humandocs/Humans/EPAR/levemir/levemir.htmDecember112009.5. European Medicine Agency: Levemir European Public Assessment Report. Revision 10, 22 July 2008. http://www.emea.europa.eu/humandocs/Humans/EPAR/levemir/levemir.htm (accessed December 11, 2009). Google Scholar6 Heise TNosek LRønn BBEndahl LHeinemann LKapitza CDraeger ELower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in subjects with type 1 diabetesDiabetes20045316141620.6. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E: Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in subjects with type 1 diabetes. Diabetes 2004;53:1614–1620. Crossref, Medline, Google Scholar7 Plank JBodenlenz MSinner FMagnes CGorzer ERegittnig WEndahl LADraeger EZdravkovic MPieber TRA double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemirDiabetes Care20052811071112.7. Plank J, Bodenlenz M, Sinner F, Magnes C, Gorzer E, Regittnig W, Endahl LA, Draeger E, Zdravkovic M, Pieber TR: A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 2005;28:1107–1112. Crossref, Medline, Google Scholar8 Russell-Jones DSimpson RHylleberg BDraeger EBolinder JEffects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimenClin Ther200426724736.8. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J: Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 2004;26:724–736. Crossref, Medline, Google Scholar9 Haak TTiengo ADraeger ESuntum MWaldhäusl WLower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetesDiabetes Obes Metab200575664.9. Haak T, Tiengo A, Draeger E, Suntum M, Waldhäusl W: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56–64. Crossref, Medline, Google Scholar10 Raslová KBogoev MRaz ILeth GGall MAHâncu NInsulin detemir, insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193–201Erratum in: Diabetes Res Clin Pract200672112.10. Raslová K, Bogoev M, Raz I, Leth G, Gall MA, Hâncu N: Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193–201. Erratum in: Diabetes Res Clin Pract 2006;72:112. Crossref, Google Scholar11 Philis-Tsimikas ACharpentier GClauson PMartinez Ravn GRoberts VLThorsteinsson BComparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetesClin Ther20062815691581.11. Philis-Tsimikas A, Charpentier G, Clauson P, Martinez Ravn G, Roberts VL, Thorsteinsson B: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569–1581. Crossref, Medline, Google Scholar12 Fritsche ASchweitzer MAHäring HU4001 Study GroupGlimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trialAnn Intern Med2003138952959.12. Fritsche A, Schweitzer MA, Häring HU; 4001 Study Group: Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952–959. Crossref, Medline, Google Scholar13 Kennedy LHerman WHStrange PHarris AGOAL A1C TeamImpact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trialDiabetes Care20062918.13. Kennedy L, Herman WH, Strange P, Harris A; GOAL A1C Team: Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurement of HbA1c on glycemic control in patients with type 2 diabetes: the Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) trial. Diabetes Care 2006;29:1–8. Crossref, Medline, Google Scholar14 Davies MStorms FShutler SBianchi-Biscay MGomis RATLANTUS Study GroupImprovement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargineDiabetes Care20052812821288.14. Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R; ATLANTUS Study Group: Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005;28:1282–1288. Crossref, Medline, Google Scholar15 Standl EMaxeiner SRaptis SHOE901/4009 Study GroupOnce-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibilityHorm Metab Res200638172177.15. Standl E, Maxeiner S, Raptis S; HOE901/4009 Study Group: Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006;38:172–177. Crossref, Medline, Google Scholar16 Rosenstock JDavies MHome PDLarsen JKoenen CShernthaner GA randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naive people with type 2 diabetesDiabetologia200851408416.16. Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Shernthaner G: A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when added to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408–416. Crossref, Medline, Google Scholar17 Holman RRThorne KIFarmer AJDavies MJKeenan JFPaul SLevy JC4-T Study GroupAddition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetesN Engl J Med200735717161730.17. Holman RR, Thorne KI, Farmer AJ, Davies MJ, Keenan JF, Paul S, Levy JC; 4-T Study Group: Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716–1730. Crossref, Medline, Google Scholar18 Koenen CHow do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?Nat Clin Pract Endocrinol Metab20084E1.18. Koenen C: How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus? Nat Clin Pract Endocrinol Metab 2008;4:E1. Crossref, Medline, Google Scholar19 Blonde LMerilainen MKarwe VRaskin PPatient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE™ studyDiabetes Obes Metab200911623631.19. Blonde L, Merilainen M, Karwe V, Raskin P: Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets—the TITRATE™ study. Diabetes Obes Metab 2009;11:623–631. Crossref, Medline, Google Scholar20 Holman RRFarmer AJDavies MJLevy JCDarbyshire JLKeenan JFPaul SK4-T Study GroupThree-year efficacy of complex insulin regimens in type 2 diabetesN Engl J Med200936117361747.20. Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, Keenan JF, Paul SK; 4-T Study Group: Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736–1747. Crossref, Medline, Google Scholar21 Selam JLKoenen CWeng WMeneghini LImproving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 studyCurr Med Res Opin2008241120.21. Selam JL, Koenen C, Weng W, Meneghini L: Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008;24:11–20. Crossref, Medline, Google Scholar22 Dornhorst ALüddeke HJKoenen CMerilainen MKing ARobinson ASreenan SPREDICTIVE Study GroupTransferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVEDiabetes Obes Metab2008107581.22. Dornhorst A, Lüddeke HJ, Koenen C, Merilainen M, King A, Robinson A, Sreenan S; PREDICTIVE Study Group: Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE. Diabetes Obes Metab 2008;10:75–81. Medline, Google Scholar23 Meneghini LFRosenberg KHKoenen CMerilainen MJLüddeke HJInsulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE studyDiabetes Obes Metab20079418427.23. Meneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Lüddeke HJ: Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007;9:418–427. Crossref, Medline, Google Scholar24 Yenigun MHonka MSwitching patients from insulin glargine-based basal–bolus regimens to a once-daily insulin detemir-based basal–bolus regimen: results from a subgroup of the PREDICTIVE™ studyInt J Clin Pract200963425432.24. Yenigun M, Honka M: Switching patients from insulin glargine-based basal–bolus regimens to a once-daily insulin detemir-based basal–bolus regimen: results from a subgroup of the PREDICTIVE™ study. Int J Clin Pract 2009;63:425–432. Crossref, Medline, Google Scholar25 King ABOnce-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover studyDiabetes Obes Metab2009116971.25. King AB: Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes Obes Metab 2009;11:69–71. Crossref, Medline, Google Scholar26 Klein OLynge JEndahl LDamholt BNosek LHeise TAlbumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetesDiabetes Obes Metab20079290299.26. Klein O, Lynge J, Endahl L, Damholt B, Nosek L, Heise T: Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007;9:290–299. Crossref, Medline, Google Scholar27 Rodbard HWJellinger PSDavidson JAEinhorn DGarber AJGrunberger GHandelsman YHorton ESLebovitz HLevy PMoghissi ESSchwartz SSStatement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic controlEndocr Pract200915540559.27. Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelsman Y, Horton ES, Lebovitz H, Levy P, Moghissi ES, Schwartz SS: Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540–559. Crossref, Medline, Google Scholar28 European Medicines Agency: European Public Assessment Report (EPAR): Levemir®EPAR summary for the publichttp://www.emea.europa.eu/humandocs/PDFs/EPAR/levemir/H-528-en1.pdfDecember112009.28. European Medicines Agency: European Public Assessment Report (EPAR): Levemir®. EPAR summary for the public. http://www.emea.europa.eu/humandocs/PDFs/EPAR/levemir/H-528-en1.pdf (accessed December 11, 2009). Google Scholar29 Novo Nordisk Canada Inc.Product Monograph Part III: Consumer Information: Levemir® (insulin detemir)http://www.novonordisk.ca/PDF_Files/LevemirPMPatient_En.pdfDecember112009.29. Novo Nordisk Canada Inc.: Product Monograph Part III: Consumer Information: Levemir® (insulin detemir). http://www.novonordisk.ca/PDF_Files/LevemirPMPatient_En.pdf (accessed December 11, 2009). Google Scholar30 Novo Nordisk Pharmaceuticals Pty. Ltd.Levemir® FlexPen® (insulin detemir [rys]): Consumer Medicine Informationhttp://www.novonordisk.co.nz/LevFpcmi3.pdfDecember112009.30. Novo Nordisk Pharmaceuticals Pty. Ltd.: Levemir® FlexPen® (insulin detemir [rys]): Consumer Medicine Information. http://www.novonordisk.co.nz/LevFpcmi3.pdf (accessed December 11, 2009). Google Scholar31 Garg SKGottlieb PAHisatomi MED'Souza AWalker AJIzuora KEChase PHImproved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargineDiabetes Res Clin Pract2004664956.31. Garg SK, Gottlieb PA, Hisatomi ME, D'Souza A, Walker AJ, Izuora KE, Chase PH: Improved glycemic control without an increase in severe hypoglycemic episodes in intensively treated patients with type 1 diabetes receiving morning, evening, or split dose insulin glargine. Diabetes Res Clin Pract 2004;66:49–56. Crossref, Medline, Google Scholar32 DeVries HPieber TNattrass MRefining basal insulin therapy: what have we learned in the age of analogues?Diabetes Metab Res Rev200723441454.32. DeVries H, Pieber T, Nattrass M: Refining basal insulin therapy: what have we learned in the age of analogues? Diabetes Metab Res Rev 2007;23:441–454. Crossref, Medline, Google ScholarFiguresReferencesRelatedDetailsCited byInsulin is not insulin and a unit not a unit4 February 2015 | Diabetes, Obesity and Metabolism, Vol. 17, No. 3The Fallacy of Hindsight: Response to Moses and Koenen Frits Holleman and J. Hans DeVries5 October 2010 | Diabetes Technology & Therapeutics, Vol. 12, No. 10 Volume 12Issue 6Jun 2010 InformationCopyright 2010, Mary Ann Liebert, Inc.To cite this article:Alan C. Moses and Christoph Koenen.Response to Swinnen et al..Diabetes Technology & Therapeutics.Jun 2010.503-505.http://doi.org/10.1089/dia.2009.0186creative commons licensePublished in Volume: 12 Issue 6: May 17, 2010PDF download